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Abstract
Francisella tularensis is a facultative intracellular pathogen and potential biothreat agent. Evasion 
of the immune response contributes to the extraordinary virulence of this organism although the 
mechanism is unclear. Whereas wild-type strains induced low levels of cytokines, an F. tularensis 
ripA deletion mutant (LVSΔripA) provoked significant release of IL-1β, IL-18, and TNF-α by 
resting macrophages. IL-1β and IL-18 secretion was dependent on inflammasome components 
pyrin-caspase recruitment domain/apoptotic speck-containing protein with a caspase recruitment 
domain and caspase-1, and the TLR/IL-1R signaling molecule MyD88 was required for 
inflammatory cytokine synthesis. Complementation of LVSΔripA with a plasmid encoding ripA 
restored immune evasion. Similar findings were observed in a human monocytic line. The 
presence of ripA nearly eliminated activation of MAPKs including ERK1/2, JNK, and p38, and 
pharmacologic inhibitors of these three MAPKs reduced cytokine induction by LVSΔripA. 
Animals infected with LVSΔripA mounted a stronger IL-1β and TNF-α response than that of mice 
infected with wild-type live vaccine strain. This analysis revealed novel immune evasive 
mechanisms of F. tularensis.
Francisella tularensis is a Gram-negative, facultative intracellular pathogen that is the 
causative agent of the zoonotic disease tularemia. The organism can be transmitted to a host 
through insect bites, handling of infected carcasses, and inhalation of aerosolized bacteria 
(1–3). F. tularensis is a potential agent of biological warfare classified as a Select Agent by 
the Centers for Disease Control and Prevention (CDC) due to its highly infectious nature; 
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∼50% mortality is caused by an infectious dose of as few as 10 bacteria via inhalation (4). 
During the Cold War, both the former Soviet Union and the United States weaponized and 
stockpiled F. tularensis in their biological weapons programs (5). The CDC also estimated 
that an F. tularensis attack would cost $5.4 billion to the society for every 100,000 infected 
individuals (6). Four subspecies of F. tularensis exist, including tularensis, holarctica, 
mediasiatica, and novicida (7). The most virulent subspecies for humans is the subspecies 
tularensis, which is found primarily in North America. Subspecies holarctica is less virulent 
and was used to generate a live vaccine strain (LVS). LVS is attenuated in humans but 
remains highly virulent for mice making LVS a useful model to study F. tularensis 
pathogenesis.
Because exposure to the respiratory tract results in the most aggressive form of tularemia, 
several laboratories have developed mouse models of pulmonary tularemia to study this 
mode of infection (8–10). Using an intranasal delivery model, the LD50 of LVS is 103 CFU 
(9). By comparison, the LD100 for the highly virulent F. tularensis subsp. tularensis strain 
SchuS4 is less than 20 CFU (11). Upon inhalation, the bacteria are restricted to the lung for 
∼36 to 48 h where the organism persists and multiplies (12). During this time, little host 
immune response occurs as evidenced by the lack of proinflammatory cytokines IL-1β, 
TNF-α, IL-6, and IFN-γ (13). Two to four days postinfection, inflammatory cells infiltrate 
the lung, and proinflammatory cytokines can be detected in vivo. By this time, bacteria have 
overwhelmed the lung and disseminated to other organs such as the spleen and liver. Mice 
eventually succumb to infection 5–7 d postinoculation. How F. tularensis circumvents the 
host immune response is not well understood.
F. tularensis is found in vivo within alveolar macrophages, dendritic cells, and lung 
epithelial cells (9). After entry into host cells, F. tularensis escapes the phagosome and 
enters the cytosol where it replicates. This process is apparently unhindered by innate 
immune defenses that typically detect and facilitate a response to eliminate foreign 
microbes. IFN-γ, TNF-α, and IL-1β are critical mediators of an effective defense against 
Francisella infection (14, 15). SchuS4 suppresses proinflammatory cytokine induction in 
mouse lung resident dendritic cells in early stages of the disease (13). Similarly, LVS 
dampens intracellular signaling and TNF-α in human monocytes and mouse macrophages 
(16). Administration of anti–IFN-γ and anti–TNF-α Abs greatly reduces the LD50 of LVS in 
an intradermal mouse model of mouse tularemia (17). IL-1β also is critical in innate defense 
against F. tularensis subsp. novicida (14). Disrupting the signaling pathway that leads to 
IL-1β processing greatly enhances host susceptibility to subspecies novicida infection.
IL-1β, one of the more potent proinflammatory cytokines, is tightly regulated by a two-step 
signaling process. The first step requires the transcriptional activation of pro–IL-1β followed 
by the translation of the proprotein. This is achieved by engagement of the TLRs and 
subsequent activation of MyD88-dependent signaling pathways, leading to NF-κB and 
MAPK induction. This leads to translocation of the NF-κB subunit p65 from the cytosol to 
the nucleus and activation of the MAPK phosphorylation cascade to cause the transcription 
of pro–IL-1β message. A second and separate signal is required after pro–IL-1β protein is 
produced, and this occurs in the cytosol, leading to the assembly of an inflammasome 
complex. There are several types of inflammasomes, including those that contain a 
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nucleotide binding domain-leucine rich repeats containing (NLR) component, and those that 
contain a non-NLR component, such as absent in melanoma 2 or retinoic acid-inducible 
gene 2 (18–22). Procaspase-1 is a requisite member of the complex, and the adaptor pyrin-
caspase recruitment domain (PYCARD)/apoptotic speck-containing protein with a CARD/
target of methylation-induced silencing is found in most inflammasome complexes (23, 24). 
Upon inflammasome formation, procaspase-1 undergoes autocatalytic cleavage into an 
active, mature form that subsequently cleaves pro–IL-1β and pro–IL-18 into their active 
forms.
NLR family members share a conserved structure, with most of the members bearing an N-
terminal pyrin or CARD domain followed by an nucleotide binding domain and a C-
terminal leucine rich repeat domain that is homologous to those found in TLRs (25). A 
current working hypothesis is that upon induction, the NLR recruits PYCARD via a pyrin–
pyrin homotypic interaction. PYCARD possesses its own CARD domain, which recruits 
caspase-1 into the inflammasome complex for IL-1β processing. Several NLRs that 
contribute to pathogen-induced IL-1β release in macrophages have been identified (26). The 
absence of NLRs or their adaptors renders hosts more susceptible to a variety of pathogens. 
The NLRP3 inflammasome senses a wide variety of intracellular pathogens including Gram-
positive and Gram-negative bacteria, RNA viruses, DNA viruses, yeast, microbial toxins, 
and a host of damage-associated molecular patterns such as silica, asbestos, and alum (27–
29). The NLRC4/Ipaf inflammasome responds to bacterial virulence factors from the type 
III and IV secretion systems from bacteria such as Salmonella typhi, Burkholderia 
pseudomallei, Escherichia coli (30–32), and Pseudomonas aeruginosa (33).
Unlike most Gram-negative bacterial pathogens, F. tularensis subsp. tularensis and F. 
tularensis subsp. holarctica do not provoke a substantial initial inflammatory response in 
vitro or in vivo (13, 33, 34). F. tularensis LPS does not stimulate significant signaling 
through TLR4 (35), but this property alone does not account for the muted host response to 
infection. The goal of this study was to identify mechanisms by which F. tularensis actively 
suppresses the host innate immune response. To achieve this goal, we used an attenuated F. 
tularensis mutant that elicited a robust inflammatory response to reveal signaling pathways 
that are normally suppressed by wild-type organisms and that dampen IL-1β, IL-18, and 
TNF-α responses to infection.
Materials and Methods
Cell lines and reagents
Bone marrow-derived macrophages (BMDMs) were harvested from 6- to 8-wk-old mice and 
cultured for 7 d in 30% M-CSF conditioned medium. THP-1 cells (American Type Culture 
Collection, Manassas, VA) were cultured as described (36). Anti–IL-1β Ab was obtained 
from R&D Systems (Minneapolis, MN); anti-IκBα, phospho-p65, phospho-ERK1/2, 
phospho-JNK, and phospho-p38 from Cell Signaling (Danvers, MA); and anti-GAPDH 
from Santa Cruz Biotechnology (Santa Cruz, CA). Detailed methods for preparation of 
retroviral shuttle vectors, transduction, and sorting to generate THP-1 cell lines stably 
expressing short hairpin RNA have been described (36).
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Western blotting and ELISA
Western blots were performed as described (37, 38). Quantification of Western blots by 
densitometry was performed using Adobe Photoshop (Adobe, San Jose, CA). For ELISAs, 
mouse and human cell supernatants were collected 24 h postinfection and assayed with BD 
OptEIA Mouse IL-1β, IL-18, and TNF-α ELISA Sets (BD Biosciences, San Diego, CA).
Cytotoxicity assays
Cytotoxicity assays were performed using the ToxiLight BioAssay kit (Lonza, Basel, 
Switzerland) following the manufacturer's protocol for detection from supernatants. The 
luminescence was read using a TECAN Infinite M200 and analyzed using Magellan v6 
software (TECAN, Mannedorf, Switzerland).
Experimental animals
All studies were conducted in accordance with the National Institutes of Health Guidelines 
for the Care and Use of Laboratory Animals and the Institutional Animal Care and Use 
Committee guidelines of the University of North Carolina, Chapel Hill. The generation of 
mice lacking functional Nlrp3, Nlrc4, Pycard, Caspase-1, and MyD88 has been previously 
described (38). C57BL/6 mice were purchased from The Jackson Laboratories (Bar Harbor, 
ME).
Bacteria preparation
F. tularensis LVS was obtained from the CDC (Atlanta, GA). F. tularensis subsp. novicida 
U112 was obtained from American Type Culture Collection. The LVSΔripA strain has been 
described (12). All Francisella strains were maintained on chocolate agar supplemented 
with 1% IsoVitaleX (BD Biosciences) and grown in Chamberlain's defined medium (39). 
Other bacteria were grown in lysogeny broth medium or brain–heart infusion medium. LVS 
and LVSΔripA were killed by incubation for 5 min at room temperature in 1 ml 2% 
paraformaldehyde in PBS, washed three times with PBS, and suspended in DMEM, 10% 
PBS. All cultures were grown at 37°C.
Francisella infection of mouse primary macrophages and human monocytic cell lines
LVS and LVSΔripA were grown overnight in Chamberlain's defined medium prior to 
infection, and U112 was grown overnight on chocolate agar prior to infection. 
Concentrations of bacteria were determined by Klett reading, and cells were exposed to the 
designated Francisella strain at the indicated multiplicity of infection (MOI). Infected cells 
were incubated at 37°C, and supernatants were harvested at select time points for cytokine 
analysis. For pharmacological assessments, cells were treated with Y-VAD-fmk (10 μM), 
U0126, SP-600125, and SB-202190 (0.5–25 μM) as described (36).
In vivo F. tularensis infection
F. tularensis LVS from an overnight culture in Chamberlain's medium was centrifuged, and 
the pellet was suspended in PBS. These suspensions were enumerated by Klett reading and 
diluted in Dulbecco's PBS for the inoculums. Wild-type 8- to 10-wk-old female C57BL/6 
mice were anesthetized with Avertin(2,2,2-Tribromoethanaol, Sigma-Aldrich, St. Louis, 
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MO), as determined by insensitivity to a toe pinch, and were then infected intranasally with 
bacterial inoculums in a 50-μl volume in Dulbecco's PBS. Mice were monitored for recovery 
from anesthesia.
Statistical analysis
Statistical significance in Figs. 1A–H, 2A–C, 3A–D, 5B–D was determined by two-way 
ANOVA followed by a Tukey post hoc test using GraphPad software (GraphPad, La Jolla, 
CA). Statistical significance in Fig. 6 was determined by two-tailed Mann–Whitney U tests 
using GraphPad software. The p values <0.05 were considered statistically significant. 
Unless otherwise specified, data are presented as the mean ± SD.
Results
F. tularensis LVSΔripA fails to suppress the release of proinflammatory cytokines IL-1β, 
IL-18, and TNF-α by mouse primary macrophages
In response to foreign microbes, macrophages secrete proinflammatory cytokines including 
IL-1β, IL-18, and TNF-α, which activate neutrophils, fibroblasts, and endothelial cells to 
mount an antimicrobial response. F. tularensis can actively downregulate host immune 
cytokine production in vivo and in vitro (7, 15). To assess the ability of F. tularensis to 
induce proinflammatory cytokines, we first compared the induction profile for the cytokine 
IL-1β in response to various bacterial pathogens in macrophages. We selected IL-1β due to 
its central role in initiating a variety of host immune defense cascades (40). Compared with 
Salmonella typhi, Klebsiella pneumoniae, and Shigella flexneri, mouse primary 
macrophages exposed to F. tularensis LVS released significantly less IL-1β (Fig. 1A) 
suggesting that F. tularensis LVS represses this particular inflammatory response. One 
possible source of this difference is the LPS. LPS from Salmonella typhi, K. pneumoniae, 
and Shigella flexneri may be more immune-stimulatory than F. tularensis LPS as described 
by another report (33).
Required for intracellular proliferation, factor A (RipA; FTL_1914) is a cytoplasmic 
membrane protein that is conserved among Francisella species and is required for 
adaptation of the bacteria to the host cell cytoplasm. Mutants lacking ripA (ΔripA strains) 
enter macrophages and escape from the phagosome at the same frequency and kinetics as 
wild-type F. tularensis but fail to replicate intracellularly in the host cell (12). In that study, 
we demonstrated that LVSΔripA was unable to replicate intracellularly in host epithelial 
cells or macrophages. We considered that ΔripA strains might also be affected in their ability 
to suppress host cell immune responses. To test this possibility, we monitored IL-1β release 
by macrophages infected with wild-type or LVSΔripA strains. Over a range of MOI, 
LVSΔripA induced ∼5- to 10-fold higher levels of IL-1β than that of wild-type–infected 
macrophages (Fig. 1B). Suppression of IL-1β was restored to LVSΔripA by in trans 
complementation with a ripA-containing construct, pripA (Fig. 1B), demonstrating a direct 
but inverse cause-and-effect relationship between F. tularensis RipA expression and IL-1β 
response.
Huang et al. Page 5













We next asked whether the effect of RipA on cytokine expression was widespread or limited 
to IL-1β. IL-18 production was measured because the inflammasome is also involved in 
processing and release of this cytokine. Increased levels of IL-18 similar to that of IL-1β 
were released by the LVSΔripA-stimulated macrophages, and complementation reduced 
induction nearly to wild-type levels (Fig. 1C). Because F. tularensis-induced TNF-α is not 
regulated by inflammasome components (14) but is regulated by MyD88 (35), we sought to 
test whether these findings hold true for LVSΔripA-induced TNF-α release. LVSΔripA 
induced 2- to 3 fold more TNF-α than that of wild-type LVS (Fig. 1D). The magnitude of 
the difference between LVS and LVSΔripA-induced TNF-α release by macrophages was 
less than that of IL-1β. This suggests that ripA affects F. tularensis suppression of both 
inflammasome and noninflammasome cytokines, but that the impact on inflammasome 
cytokines is more significant. Neither paraformaldehyde (PFA)-fixed wild-type LVS nor 
LVSΔripA mutant strains provoked significant levels of IL-1β (Fig. 1E) demonstrating that 
the observed impact of RipA on cytokine expression was not due simply to lack of 
intracellular replication by the deletion mutant strain.
One possible mechanism for the different levels of IL-1β induced by LVS versus LVSΔripA 
is that the former might cause more cell death, thus interfering with IL-1β production and 
processing. To assess cell viability differences between LVS and LV S ΔripA, we measured 
cytotoxicity of primary mouse macro-phages postinfection with LVS, LVSΔripA, or the 
LVS ripA complementation strain. As shown in Fig. 1F, infection with LVSΔripA resulted 
in increased cytotoxicity compared with cells infected with wild-type LVS or the ripA 
complementation strain. These data together suggest that LVSΔripA is both hyper-
inflammatory and hypercytotoxic compared with wild-type LVS. These results are 
consistent with the frequent association of inflammasome activation and cell death (41), as 
shown here for LVSΔripA, but inconsistent with the possibility that LVS causes more cell 
death, which interferes with IL-1β production and release.
To address further the potential contribution of MOI to the observed phenotypes, primary 
mouse macrophages were exposed to wild-type LVS at MOI 10, 50, or 500, and IL-1β 
secretion was assayed by ELISA at 24 h postinfection. As shown in Fig. 1G, IL-1β 
production increased with MOI; however, the levels of IL-1β produced at the lower MOI of 
10 was near the limit of detection. Therefore, for the subsequent LVS infections in primary 
mouse macrophages, MOI 50 or 500 was used.
In contrast with the relatively low levels of IL-1β that we observe for wild-type LVS, several 
studies have shown that infection with subspecies novicida results in high levels of 
IL-1βsecretion and cell death, albeit the Mariathasan et al. (14) study used LPS-pretreated, 
thioglycolate-elicited peritoneal macrophages (42). To determine if the differences in IL-1β 
secretion are strain-specific, we infected resting BMDMs with F. tularensis subsp. novicida 
U112 at MOI 10, 100, or 500 and assayed for IL-1β secretion at 24 h postinfection (Fig. 
1H). Similar to the results of Henry et al. (42) for subspecies novicida-induced IL-1β 
secretion in BMDMs, our data shows that subspecies novicida strain U112 induced higher 
levels of IL-1β secretion by primary mouse macrophages (Fig. 1H).
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LVSΔripA-induced IL-1β is PYCARD, caspase-1, and MyD88 dependent
In the regulation of IL-1β release by macrophages, bacterial-derived pathogen-associated 
molecular patterns or microbe-associated molecular patterns first activate the TLR signaling 
pathway, thereby promoting the synthesis of pro–IL-1β transcript and later protein. A second 
signal initiates assembly of the inflammasome to process pro–IL-1β into IL-1β for release. 
To determine the level at which IL-1β release is regulated upon infection, we tested whether 
disruption of either TLR or NLR/inflammasome signaling pathways can abrogate 
LVSΔripA-induced IL-1β release. MyD88 was chosen for TLR signaling due to its central 
role in TLR/IL-1R pathways. To disrupt inflammasome formation, mice deficient in either 
Pycard or Caspase-1 were used because these two gene products are critical in subspecies 
novicida-induced IL-1β release by mouse macrophages and the ulceroglandular form of 
tularemia (14). Furthermore, two commonly interacting NLRs, NLRP3 and NLRC4, were 
tested because they are critical in the detection and response to several pathogens (26). In 
the absence of Pycard, Caspase-1, and MyD88, macrophages did not release IL-1β upon 
LVS or LVSΔripA exposure (Fig. 2A). However, absence of Nlpr3 or Nlrc4 did not impair 
the LVSΔripA-induced release of IL-1β suggesting that these NLRs are not involved in the 
sensing of F. tularensis.
Similar to IL-1β release, PYCARD, caspase-1, and MyD88 but not NLRP3 or NLRC4 were 
required for LVSΔripA-induced IL-18 release by macrophages, further confirming effects on 
an additional inflammasome cytokine (Fig. 2B). As expected, MyD88 but not PYCARD, 
caspase-1, NLRP3, or NLRC4 is required for LVSΔripA-induced release of the 
noninflammasome cytokine TNF-α by primary mouse macrophages (Fig. 2C). Taken 
together, LVSΔripA-induced IL-1β production is mediated by PYCARD, caspase-1, and 
MyD88, which suggests that F. tularensis LVS may target the PYCARD/caspase-1 axis as 
well as other TLR-dependent signaling pathways to suppress IL-1β release by macrophages.
F. tularensis LVSΔripA fails to suppress proinflammatory cytokine response by human 
monocytic THP-1 cells
To determine if the observed effects are also applicable to human cells, we measured 
cytokine expression by the human monocytic cell line THP-1 in response to wild-type LVS 
and LVSΔripA. THP-1 cells exposed to LVSΔripA released 10-fold more IL-1β (Fig. 3A) 
and 2- to 3-fold more TNF-α (Fig. 3B) than that of cells exposed to wild-type LVS, which is 
consistent with the mouse primary macrophage response. Also consistent, the difference in 
amount of TNF-α induced between LVS and LVSΔripA is of smaller magnitude than that of 
IL-1β.
We next investigated whether PYCARD/apoptotic speck-containing protein with a CARD 
was required for LVSΔripA-induced IL-1β release by THP-1 cells using cells stably 
expressing either a control scramble PYCARD retroviral ShRNA vector (Sh-Ctrl) that does 
not confer knock down, a specific PYCARD retroviral ShRNA vector (Sh-PYCARD) to 
knock down PYCARD, or a specific NLRP3 retroviral ShRNA vector (Sh-NLRP3) to knock 
down NLRP3 (36). In our previous studies, all pathogens investigated induced IL-1β in a 
PYCARD-dependent manner in a system where PYCARD expression was reduced by short 
hairpin RNA (36). Cells were infected with LVS and LVSΔripA, and IL-1β was monitored. 
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24 h postinfection, Sh-PYCARD–bearing THP-1 cells treated with either LVS or LVSΔripA 
did not release detectable IL-1β (Fig. 3C). In contrast, induction of IL-1β release was similar 
in Sh-NLRP3–bearing cells and Sh-Ctrl–bearing cells. This is consistent with our studies 
using gene-deficient mouse primary macrophages. To determine whether caspase-1 is 
required for LVSΔripA-induced IL-1β release by THP-1 cells, THP-1 cells were pretreated 
with a specific caspase-1 inhibitor (10 μM Y-VAD-fmk). Porphyromonas gingivalis, which 
induces a caspase-1–dependent IL-1β release in THP-1 cells (37), served as control. Y-VAD 
blocked IL-1β release in response to infection with P. gingivalis, and also with LVS and 
LVSΔripA (Fig. 3D). Based on this data, we concluded that PYCARD and caspase-1 are 
required in LVSΔripA-induced IL-1β release by human monocytic THP-1 cells.
F. tularensis LVSΔripA fails to suppress the processing and synthesis of IL-1β
To elucidate the mechanisms by which F. tularensis suppresses host macrophage release of 
proinflammatory cytokines, we first sought to determine kinetics of intracellular IL-1β 
synthesis and processing using Western blot analysis to detect pro–IL-1β (33 kDa) and 
processed IL-1β (17 kDa) present in LVSΔripA-infected mouse macrophages over a time 
course postinoculation. Pro–IL-1β levels increased starting at 30 min after LVSΔripA 
exposure (Fig. 4A), a time corresponding with the kinetics of phagosome escape by both 
wild-type F. tularensis and LVSΔripA (12). IL-1β processing occurred 30–45 min 
postinfection, and processed IL-1β accumulated over several hours (Fig. 4A). By 24 h post-
infection, the intracellular level of processed IL-1β decreased, likely due to release of IL-1β 
into the extracellular space and death of macrophages. To determine whether the response to 
LVS and LVSΔripA differs in the synthesis and processing of IL-1β by macrophages, we 
repeated a time course of infection. By 60 min, LVS induced the synthesis of pro–IL-1β, and 
no processed IL-1β was evident. Pro–IL-1β increased significantly 120 min post-inoculation 
with LVS; however, only a small fraction of the pro-protein was processed to mature IL-1β 
at this point as shown by Western blotting for pro–IL-1β and processed IL-1β (Fig. 4B) and 
quantification of processed IL-1β by densitometry (Fig. 4C). In contrast, pro–IL-1β was 
present in LVSΔripA-infected macro-phages by 60 min postinfection, with the majority 
processed to mature IL-1β. Pro–IL-1β continued to increase by 120 min postinoculation, 
with half of the proprotein processed to mature IL-1β.
Next, we sought to determine if F. tularensis LVS also disrupted the synthesis of pro–IL-1β. 
To accomplish this objective, we exposed Pycard−/− mouse primary macrophages to LVS 
and LVSΔripA and monitored the synthesis of pro–IL-1β. Because the absence of PYCARD 
abolishes the processing of pro–IL-1β into mature IL-1β, we can directly compare the 
macrophage synthesis of pro–IL-1β. In the absence of IL-1β processing, LVSΔripA-infected 
macrophages induced significantly more pro–IL-1β than LVS as shown by Western blot 
(Fig. 4D) and quantified by densitometry in Fig. 4E. Only pro–IL-1β is observed in LVS and 
LVSΔripA-infected Pycard−/− BMDMs because the absence of PYCARD prevents 
processing of IL-1β. Thus, F. tularensis LVS disrupts both the synthesis and processing of 
pro–IL-1β by macrophages. Collectively, these data suggest that the removal of RipA 
affected signaling pathways required for both the synthesis and processing of pro–IL-1β.
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The effect of RipA on both pro–IL-1β and TNF-α synthesis led us to test the effect of RipA 
on pathways that can affect the production of both cytokines. Because NF-κB is a master 
transcriptional regulator that controls a wide range of host immune responses, including 
cytokine production, we sought to determine if F. tularensis LVS interfered with NF-κB 
signaling in macro-phages. Degradation of IκBα and phosphorylation of p65 were 
monitored because both events are involved in NF-κB activation. Degradation of IkBa 
allows phosphorylation and translocation of p65 into the nucleus, where p65 then binds to 
promoters of proinflammatory genes. LVS and LVSΔripA each induced degradation of 
IκBα 30–60 min postinfection and phosphorylation of p65 15–30 min postinfection (Fig. 
4F). LVSΔripA appeared to induce slightly faster degradation of IκBα and phosphorylation 
of p65; however, these small differences alone are unlikely to account for the significant 
differences between LVSΔripA and LVS in the induction of TNF-α and pro–IL-1β.
F. tularensis LVSΔripA fails to dampen the activation of MAPK pathways
Another common group of signaling pathways that contributes to cytokine activation by 
bacteria and bacterial components are the MAPK pathways. F. tularensis LVS initially 
activates MAPK signaling pathways but subsequently downregulates their activity (43). To 
determine whether the difference between the cytokine activation by LVS and LVSΔripA 
might be explained by differences in the induction of MAPKs, we profiled the 
phosphorylation of ERK1/2, JNK, and p38 in macrophages postinfection. LVS induced 
modest levels of ERK1/2 and p38 phosphorylation, which peaked at 30 and 60 min, but 
induced very little JNK activation (Fig. 5A). In contrast, LVSΔripA induced dramatic levels 
of ERK1/2 phosphorylation at 15–30 min and of JNK and p38 at 30– 60 min 
postinoculation. These data suggest that LVS dampened the induction of MAPK signaling 
pathways by a mechanism that is missing or ineffective in the ΔripA mutant strain.
To determine whether differences in MAPK activation might explain the increased 
inflammatory nature of LVSΔripA, we abrogated MAPK activity in ΔripA-infected cells 
with pharmacological inhibitors of ERK, JNK, and p38 signaling pathways. Primary mouse 
macrophages were treated with U0126, SP-600125, or SB-202190 to prevent the 
phosphorylation of ERK1/2, JNK, and p38, respectively. These cells were subsequently 
exposed to either LVS or LVSΔripA, and IL-1β release was measured 24 h postinfection. 
Both U0126 and SP-600125 reduced the release of IL-1β by macrophages by 1.5- to 2-fold 
postinfection with LVSΔripA over a range of doses (Fig. 5B). Thus, ERK and JNK 
pathways each partially contribute to IL-1β activation in ΔripA-infected cells. The addition 
of U0126 or SP-600125 also reduced the release of TNF-α by macrophages upon exposure 
to LVS and LVSΔripA (Fig. 5C). Finally, the combination of ERK, JNK, and p38 inhibitors 
blocked LVSΔripA-induced IL-1β release by macrophages more effectively than each 
inhibitor alone (Fig. 5D). Taken together, these data demonstrate that wild-type F. tularensis 
LVS interferes with the activation of multiple MAPK signaling pathways that are important 
for release of cytokines post-infection.
F. tularensis LVSΔripA fails to suppress proinflammatory cytokine responses in vivo
Our previous study showed that LVSΔripA is attenuated in mice as evidenced by a reduction 
in organ burden at days 1, 3, and 7 postintranasal infection compared with that of LVS (12). 
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In this study, we confirm and expand this finding by monitoring mice morbidity, mortality, 
and cytokine responses postinfection. Mice were intranasally inoculated with LVS, 
LVSΔripA, and mock/PBS, and weight loss was monitored among the three experimental 
groups. When using a LD100 dose of LVS (105), LVS-inoculated animals exhibited severe 
weight loss, a measure of the severity of respiratory tularemia, and eventually succumbed to 
the disease (Fig. 6A). In contrast, LVSΔripA-inoculated animals only showed a modest 
weight loss compared with that of mock/PBS-treated animals. We also measured the 
bacterial burdens in the lungs of mice during the early stages of the disease (6 and 24 h 
postinfection). Similar lung burdens were observed 6 h post-infection when comparing LVS 
and LVSΔripA, indicating that the initial bacterial loads of LVS and LVSΔripA are 
indistinguishable (Fig. 6B). By 24 h postinoculation, LVS lung burdens rose to 106 CFU/
organ. In contrast, the lung burden of LVSΔripA-inoculated animals did not increase beyond 
that of the 6-h time point. In our previous report, the ripA complementation strain of 
LVSΔripA-inoculated animals exhibited similar lung, spleen, and liver burdens compared 
with that of LVS-inoculated animals (12).
The in vitro analyses shown earlier indicate that LVSΔripA failed to suppress the release of 
IL-1β, IL-18, and TNF-α by primary mouse macrophages and human THP-1 cells. To 
determine if the absence of ripA similarly affected cytokine responses in vivo, we measured 
IL-1β and TNF-α in the lungs of infected mice. After testing multiple doses of LVSΔripA to 
determine the amount required to detect IL-1β and TNF-α in the lung (Fig. 6C), we found 
that mice inoculated with 1010 CFU LVSΔripA expressed on average 5- to 10-fold more 
IL-1β than that of animals inoculated with the same number of wild-type LVS (Fig. 6D). 
Notably, at that dose of bacteria, IL-1β levels in the bronchoalveolar lavage fluid (BALF) of 
animals infected with wild-type LVS was indistinguishable from mock/PBS-treated mice. 
We next examined levels of TNF-α in mouse lungs of mock/PBS, LVS, and LVSΔripA-
inoculated animals. LVSΔripA induced more TNF-α than did LVS, but the difference was 
not as significant as that for IL-1β (Fig. 6E). These results are consistent with the in vitro 
results obtained with mouse and human cells (Figs. 1D, 3B) and support the effects of ripA 
deletion on both inflammasome and noninflammasome mediated cytokines. Taken together, 
these data suggest that the expression of ripA in LVS suppresses macrophage 
proinflammatory cytokine production during an infection both in vitro and in vivo.
Discussion
The innate immune response is indispensable to eradicate the invasion of microbial 
pathogens, and monocytes/macrophages are major arsenals in combating infectious diseases. 
Proper release of cytokines and chemokines by these cells is critical in the migration of 
polymorphonuclear cells and other effector cells to the site of infection. To establish a 
successful infection, a pathogen must either evade immune surveillance or modulate host 
antimicrobial response. Over time, pathogens have developed sophisticated strategies to 
manipulate host immune responses to their advantage. In this study, we demonstrated that F. 
tularensis actively suppresses the release of proinflammatory cytokines and that the F. 
tularensis gene ripA is critical in this process. In response to F. tularensis LVSΔripA, 
macrophages are able to mount an effective initial response by releasing higher amounts of 
IL-1β, IL-18, and TNF-α compared with that of LVS. This observation is also seen in vivo, 
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which correlates with the reduced morbidity caused by LVSΔripA. These data suggest that 
ripA contributes to effective suppression of host immunity, and hence F. tularensis survival. 
Of equal importance is the role of IFN-γ and IFN-β during host response to F. tularensis, and 
it would be interesting to test whether the IFN-β and IFN-γ responses are altered in 
LVSΔripA-treated cells and animals during an infection.
An emerging theme in the literature is that a variety of pathogens can suppress IL-1β release 
by macrophages. P. aeruginosa induces the release of IL-1β by macrophages in a NLRC4-
dependent manner (32). A subset of P. aeruginosa expresses the effector molecule ExoU, 
and this molecule inhibits caspase-1 activation thereby preventing the release of IL-1β and 
IL-18 by macro-phages. Mycobacterium tuberculosis circumvents both innate and adaptive 
immune responses. Similar to our observations with F. tularensis, the M. tuberculosis gene 
product zmp1 prevents the activation of the inflammasome to inhibit IL-1β processing (44). 
Among viruses, myxoma virus inhibits release of proinflammatory cytokines IL-1β, IL-18, 
TNF-α, IL-6, and MCP-1. Myxoma virus encodes a pyrin-containing protein m103, which 
has been shown to bind to PYCARD and thereby disrupt the activation of inflammasome 
(45). The m103 protein also binds NF-κB, which suppresses the degradation of IκBα and 
phosphorylation of IKK. Cowpox virus, via gene crmA, directly inhibits caspase-1 activity 
and suppresses IL-1β response to infection (46). Our study with F. tularensis LVS and 
LVSΔripA together with these and other reports exemplifies the multiple strategies 
employed by pathogens to disrupt host immune activation of the production of IL-1β and 
other cytokines by innate immune cells.
To elucidate the pathways by which LVS suppresses the IL-1β release by macrophages, we 
have identified PYCARD, caspase-1, and MyD88 mediated signaling that the LVS strain 
can disrupt. Mariathasan and coworkers (14) have shown that PYCARD and caspase-1 
mediated host IL-1β production is key in combating subspecies novicida infection. In their 
study, mice lacking Pycard or Caspase-1 were far more susceptible to challenge by F. 
tularensis subsp. novicida. Moreover, mice i.p. injected with IL-18 and IL-1β neutralization 
Ab prior to subspecies novicida challenge exhibited higher organ burdens than those treated 
with isotype control, further suggesting the importance of IL-1β and IL-18 in tularemia. 
Recently, absent in melanoma 2 has been identified as candidate proteins required in F. 
tularensis-induced inflammasome formation and subsequent IL-1β release (19, 47, 48). Thus 
far, TLR2, MyD88, and type I IFN-β have been implicated in F. tularensis-induced host 
cytokine response, including IL-1β by macrophages (14, 35, 49–51). Our data suggest that 
F. tularensis LVSΔripA-induced IL-1β is PYCARD, caspase-1, and MyD88 dependent and 
that LVS disrupts these signaling pathways.
In macrophages and epithelial cells, pathogen-associated molecular patterns or microbe-
associated molecular patterns activate NF-κB and MAPK pathways to initiate the 
proinflammatory responses. There are three major families of MAPK including the ERKs, 
the JNKs, and the p38 kinases (52). Many pathogens have developed strategies to disrupt the 
MAPK pathway to subvert the immune response. Arbibe and coworkers (53) demonstrated 
that Shigella flexneri virulence factor OspF inactivates ERK1/2 and p38 by preventing their 
phosphorylation. YopJ, a type III effector protein of Yersinia species, has been shown to 
acetylate the serine and threonine residues on MAPK kinase thereby interrupting the 
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downstream MAPK phosphorylation (54). Telepnev and co-workers (43) have demonstrated 
that LVS may interfere with MAPK signaling pathways and that iglC is critical in this 
process. Our data suggest that LVS may be able to interfere with both the synthesis and 
processing of IL-1β at multiple points and that ripA is critical in these processes. The 
degradation of IκBα and phosphorylation of p65 is not likely the major mechanism by 
which ripA mediates immune suppression. However, LVSΔripA induced a significant 
increase in phosphorylation of these three MAPKs compared with that of wild-type LVS. 
Moreover, our studies showed that the LVSΔripA-induced IL-1β and TNF-α release can be 
partially reduced by pretreating cells with inhibitors of ERK, JNK, and p38 alone, and the 
use of all three inhibitors resulted in an additive reduction of cytokine production that 
approaches the lower level caused by LVS infection. These results further validate that ripA 
contributes to the MAPK suppressive nature of F. tularensis. LVS synergistically 
downregulates the synthesis of pro–IL-1β and prevents the processing of IL-1β, thereby 
resulting in strong suppression of IL-1β release by macrophages.
A specific function for RipA protein has not yet been identified. Our experiments using 
PFA-killed LVS and LVSΔripA demonstrated that RipA-mediated suppression of the 
induction of IL-1β by LVS-infected host cells is an active process. In other words, the 
induction is not solely the result of gross morphological change in the bacterial cell or a cell 
surface marker that is present in LVSΔripA regardless of the bacterial viability. Preliminary 
data from our laboratory also indicate that the outer membrane profile and LPS profile of 
LVSΔripA is unchanged. Furthermore, our previous study demonstrated that RipA is 
localized to the cytoplasmic membrane of F. tularensis (12). This finding suggests that RipA 
does not mediate immune response suppression by directly interfering with or binding to 
innate immune receptors or sensors. More likely, RipA is interacting with another protein or 
proteins that interfere with the proinflammatory signaling pathways.
Others have also found that infection of macrophages with LVS blocks TLR-induced 
signaling (43); however, there are seemingly conflicting reports that F. tularensis subsp. 
novicida or LVS is a potent inducer of proinflammatory cytokines (14, 33, 55, 56). These 
apparent contradictions may be due to variations in the experimental designs, such as the 
differences in MOI, the activation state of the cell population used, or the different 
subspecies used. Ulland et al. (56) reported nanogram levels of IL-1β secretion from LPS-
prestimulated BMDMs that were subsequently infected with LVS, whereas we infected 
naive BMDMs. We also have found that after prestimulation of BMDMs with E. coli LPS, 
LVS induced high levels of IL-1β (data not shown). Thus, the activation state of the cell 
likely affects the cytokine levels produced in response to F. tularensis. Consistent with this 
possibility, Cole et al. (55) found substantial LVS-induced IL-1β response by thioglycolate-
elicited peritoneal macrophages. We believe that the use of nonstimulated macrophages, as 
in our study, might better reflect the host response during a primary infection.
An additional difference between our study and the latter is that our study primarily used 
LVS at MOIs of 50 to 500, whereas the study by Cole and colleagues (55) used MOIs of 5 
to 10. We found that infection of resting macrophages with a low MOI of LVS induced little 
IL-1β, and the increased MOI is therefore unlikely to explain the difference in cytokine 
induction levels. Furthermore, the fact that LVSΔripA is both hyperinflammatory and 
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hypercytotoxic compared with wild-type LVS suggests that differences in cell death 
induction in LVS cannot explain the differences in IL-1β production and release (Fig. 1F). 
Finally, it is possible that these differences are due to infection by different subspecies. F. 
tularensis subsp. novicida, a less virulent subspecies, caused substantial IL-1β and IL-18 
production and caspase-1–dependent cell death at the low MOI (14). Likewise, we found 
that a similar range of doses of subspecies novicida U112 caused a significant amount of 
IL-1β release in resting BMDMs (Fig. 1H), whereas LVS did not (Fig. 1G). This suggests 
that the high levels of IL-1β in other studies relative to ours might also be explained by the 
use of different F. tularensis subspecies. Although we acknowledge that LVS may induce 
various levels of cytokines depending on the methods of preparing primary mouse 
macrophages, it is clear that the deletion of ripA alleviated the immunosuppressive nature of 
LVS with respect to IL-1β and TNF-α.
In conclusion, we elucidated a mechanism by which F. tularensis actively evades host 
immune response by an analysis of the attenuated LVSΔripA strain. These results indicate 
that the ripA gene product functions by targeting two prominent innate immune circuits: the 
circumvention of the host inflammasome response and the dampening of the activation of 
MAPK signaling pathways. During the review of this article, there was a report of another 
immune evasion gene in LVS that when removed resulted in elevated IL-1β and cell death 
accompanied by reduced in vivo bacterial replication (56). Thus, the phenomenon described 
in our study might be a common pathway for immune evasion by F. tularensis.
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Abbreviations used in this paper
BMDM bone marrow-derived macrophage
BALF bronchoalveolar lavage fluid
CARD caspase recruitment domain
CDC Centers for Disease Control and Prevention
LVS live vaccine strain
MOI multiplicity of infection
NLR nucleotide binding domain-leucine rich repeats containing
PFA paraformaldehyde
PYCARD pyrin-CARD
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RipA required for intracellular proliferation, factor A
Z-VAD-fmk Z-Tyr-Val-Ala-Asp-fluoromethylketone
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F. tularensis LVSΔripA fails to suppress proinflammatory cytokine release by primary 
mouse macrophages. A, IL-1β secretion levels in mouse macrophages after exposure to F. 
tularensis LVS, Salmonella typhi, K. pneumoniae, or Shigella flexneri at MOI 50 for 24 h as 
determined by ELISA. Data represent mean ± SD for at least three independent experiments 
performed in triplicate. A representative experiment is shown. B, IL-1β secretion levels in 
mouse macrophages exposed to LVS, LVSΔripA, or LVSΔripA complementation strain at 
MOI 50 and 500 for 24 h. Data represent mean ± SD for at least three independent 
experiments performed in triplicate. A representative experiment is shown. C, IL-18 
secretion levels in mouse macrophages exposed to LVS, LVSΔripA, or LV S ΔripA 
complementation strain at MOI 50 and 500 for 24 h. Data represent mean ± SD for at least 
three independent experiments performed in triplicate. A representative experiment is 
shown. D, TNF-α secretion levels in mouse macrophages exposed to LVS, LVSΔripA, or 
LVSΔripA complementation strain at MOI 50 and 500 for 24 h. Data represent mean ± SD 
for at least three independent experiments performed in triplicate. A representative 
experiment is shown. E, IL-1β secretion levels in mouse macrophages exposed to live and 
PFA-treated LVS and LVSΔripA at MOI 50 and 500 for 24 h. Data represent mean ± SD for 
at least three independent experiments performed in triplicate. A representative experiment 
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is shown. F, Cytotoxicity of mouse macrophages exposed to LVS, LVSΔripA, or LVSΔripA 
complementation strain at MOI 500 for 24 h as measured by luminescence. Data represent 
mean ± SD for at least three independent experiments performed in duplicate or triplicate. A 
representative experiment is shown. G, IL-1β secretion levels in mouse macrophages 
exposed to LVS at MOI 10, 50, and 500 for 24 h. Data represent mean ± SD for at least 
three independent experiments performed in triplicate. A representative experiment is 
shown. H, IL-1β secretion levels in mouse macrophages exposed to U112 at MOI 10, 100, 
and 500 for 24 h. Data represent mean ± SD for at least three independent experiments 
performed in triplicate. A representative experiment is shown. *p < 0.05.
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LVSΔripA induced proinflammatory cytokines are regulated by inflammasome components 
and MyD88. A, IL-1β secretion levels in mouse macrophages derived from Wt, Pycard−/−, 
Caspase-1−/−, MyD88−/−, Nlrp3−/−, and Nlrc4−/− mice exposed to LVS and LVSΔripA at 
MOI 500 for 24 h as assessed by ELISA of cell supernatants. Data represent mean ± SD for 
at least three independent experiments performed in triplicate. A representative experiment 
is shown. B, IL-18 secretion levels in macrophages derived from Wt, Pycard−/−, 
Caspase-1−/−, MyD88−/−, Nlrp3−/−, and Nlrc4−/− mice exposed to LVS and LVSΔripA at 
MOI 500 for 24 h. Data represent mean ± SD for at least three independent experiments 
performed in triplicate. A representative experiment is shown. C, TNF-α secretion levels in 
mouse macrophages derived from Wt, Pycard−/−, Caspase-1−/−, MyD88−/−, Nlrp3−/−, and 
Nlrc4−/− exposed to LVS and LVSΔripA at MOI 500 for 24 h. Data represent mean ± SD for 
at least three independent experiments performed in triplicate. A representative experiment 
is shown. *p < 0.05.
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LVS ripA is necessary for suppression of proinflammatory cytokine release by human 
THP-1 cells. A, IL-1β secretion levels in THP-1 cells exposed to LVS and LVSΔripA at 
MOI 500 for 24 h. Data represent mean ± SD for at least three independent experiments 
performed in triplicate. A representative experiment is shown. B, TNF-α secretion levels in 
THP-1 cells exposed to LVS and LVSΔripA at MOI 500 for 24 h. Data represent mean ± SD 
for at least three independent experiments performed in triplicate. A representative 
experiment is shown. C, IL-1β secretion levels in THP-1 cells expressing stable Sh-Ctrl, Sh-
PYCARD, and Sh-NLRP3 exposed to LVS and LVSΔripA at MOI 500 for 24 h. Data 
represent mean ± SD for at least three independent experiments performed in triplicate. A 
representative experiment is shown. D, IL-1β secretion levels in mock pretreated THP-1 
cells and cells pretreated with Y-VAD and exposed to LVS and LVSΔripA at MOI 500 for 
24 h. Data represent mean ± SD for at least three independent experiments performed in 
triplicate. A representative experiment is shown. *p < 0.05.
Huang et al. Page 21














F. tularensis LVS suppresses IL-1β response in macrophages by interfering with IL-1β 
synthesis and processing. A, Western blot analysis of IL-1β expression in mouse 
macrophages exposed to LVSΔripA at MOI 500 for 0, 5, 15, 20, 30, 45, 60, 120, 180 min 
and 24 h. At least three independent experiments were performed. A representative Western 
blot is shown. B, Western blot analysis of IL-1β expression in mouse macrophages exposed 
to LVS and LVSΔripA at MOI 500 for 0, 15, 30, 60, and 120 min. At least three independent 
experiments were performed. A representative Western blot is shown. C, Densitometric 
quantification of the bands for processed IL-1β (17 kDa) shown in B. D, Western blot 
analysis of IL-1β expression in macrophages derived from Pycard−/− mice after exposure to 
LVS and LVSΔripA at MOI 500 for 0, 30, 60, and 120 min. At least three independent 
experiments were performed. A representative Western blot is shown. E, Densitometric 
quantification of the bands for pro–IL-1β (33 kDa) shown in D. F, Western blot analysis of 
IκBα and phospho-p65 in mouse macrophages exposed to LVS and LVSΔripA at MOI 500 
for 0, 15, 30, and 60 min. At least three independent experiments were performed. A 
representative Western blot is shown.
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F. tularensis LVS suppresses proinflammatory cytokine release by disrupting MAPK 
signaling pathways A, Western blot analysis of phospho-ERK1/2, phospho-JNK, phospho-
p38, and GAPDH in mouse macrophages exposed to LVS and LVSΔripA at MOI 500 for 0, 
15, 30, and 60 min. At least three independent experiments were performed. A 
representative Western blot is shown. B, IL-1β secretion levels in mouse macrophages 
pretreated with ERK inhibitor U0126 and JNK inhibitor SP-600125 and exposed to LVS and 
LVSΔripA at MOI 500 for 24 h. Data represent mean ± SD for at least three independent 
experiments performed in triplicate. A representative experiment is shown. C, TNF-α 
secretion levels in mouse macrophages pretreated with U0126 or SP-600125 and exposed to 
LVS or LVSΔripA at MOI for 24 h. Data represent mean 6 SD for at least three independent 
experiments performed in triplicate. A representative experiment is shown. D, IL-1β 
secretion levels in mouse macrophages pretreated with U0126, SP-600125, p38 inhibitor 
SB-202190, or a combination of U0126, SP-600125, and SB-202190 and exposed to LVS or 
LVSΔripA at MOI 500 for 24 h. Data represent mean ± SD for at least three independent 
experiments performed in triplicate. A representative experiment is shown. *p < 0.05.
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LVSΔripA fails to suppress proinflammatory cytokine responses in a mouse respiratory 
tularemia model. A, Body weights of mice intranasally exposed to mock, LVS, and 
LVSΔripA at dose of 105 for 1–10 d. At least two independent experiments with seven 
animals per experimental condition (PBS, LVS, and LVSΔripA) were performed. A 
representative experiment is shown. B, Lung organ burdens of mice intranasally exposed to 
LVS and LVSΔripA at a dose of 105 for 6 and 24 h. At least three independent experiments 
with more than four animals per group were performed. Each symbol represents one animal. 
A representative experiment is shown. C, IL-1β levels in mouse BALF after intranasal 
exposure to LVSΔripA at increasing doses for 24 h. Data represent mean ± SD for at least 
two independent experiments with more than three animals per group. Each symbol 
represents one animal. A representative experiment is shown. D, IL-1β levels in mouse 
BALF after mock treatment or intranasal exposure to LVS or LVSΔripA (1010 bacteria per 
animal for both LVS and LVSΔripA) for 24 h. Data represent mean ± SD for at least three 
independent experiments with more than six animals per group. Each symbol represents one 
animal. All data are shown. E, TNF-α levels in mouse BALF after mock treatment or 
intranasal exposure LVS or LVSΔripA (1010 bacteria per animal for both LVS and 
LVSΔripA) for 24 h. Data represent mean ± SD for at least two independent experiments 
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with more than six animals per group. Each symbol represents one animal. All data are 
shown. *p < 0.05.
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